300
Participants
Start Date
December 1, 2022
Primary Completion Date
July 31, 2025
Study Completion Date
December 31, 2025
ATG
Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT, with G-CSF/ATG based protocol.
Post-transplantation cyclophosphamide
Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
RECRUITING
People's Hospital of Peking University, Beijing
Collaborators (1)
Sanofi
INDUSTRY
Peking University People's Hospital
OTHER